secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2023-04-28T23:59:59+00:00
Accession:  0001104659-23-052948
Event type: leadership
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics CFO Salvatore Calabrese departs; severance includes pay and equity acceleration
--------------------------------------------------------------------------------

- CFO Salvatore Calabrese terminates April 30, 2023; severance includes €249,827 (12 months' salary) and €41,638 bonus.
- Unvested equity awards accelerate 100% vesting; options exercisable 12 months after termination.
- Additional change-of-control benefits available if triggered before April 30, 2024, less severance paid.
- Mutual non-disparagement and cooperation provisions; full release of claims against the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465923052948/0001104659-23-052948-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465923052948/tm2313505d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-052948

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer